查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961398

良性前列腺增生治疗设备市场－全球产业规模、份额、趋势、机会、预测：按类型、最终用户、地区和竞争格局划分，2021-2031年

Benign Prostatic Hyperplasia Treatment Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球良性摄护腺增生 (BPH) 治疗设备市场预计将从 2025 年的 115.6 亿美元成长到 2031 年的 149.8 亿美元，复合年增长率为 4.41%。

该市场涵盖用于治疗良性前列腺增生（BPH）的微创和外科手术医疗设备，包括电切镜、雷射系统和射频消融设备等技术。推动这一市场成长的主要因素是全球人口快速老化以及人们越来越倾向于选择能够加速患者康復的微创手术。老年男性中BPH的高发生率是造成此需求的主要原因。例如，美国泌尿系统协会在2024年报告称，65岁及以上男性中良性前列腺增生及相关下泌尿道症状的盛行率在29%至35%之间。

市场概览
预测期 2027-2031
市场规模：2025年 115.6亿美元
市场规模：2031年 149.8亿美元
复合年增长率：2026-2031年 4.41%
成长最快的细分市场 雷射设备
最大的市场 北美洲

儘管市场需求强劲，先进外科技术所需的巨额资本投资仍是市场扩张的一大障碍。安装和维护最新雷射主机和机器人系统的高成本会限制其普及率，尤其是在采购预算紧张的医疗机构。因此，在成本敏感地区，这种经济障碍往往迫使医疗机构依赖传统的（效率较低的）方法，减缓了新设备解决方案的推广应用。

市场驱动因素

良性前列腺增生（BPH）盛行率的上升，其根本原因在于全球男性人口老化，这需要持续增加诊断和治疗设备的应用。随着预期寿命的延长，需要干预治疗下泌尿道症状的患者人数不断增长，医疗机构必须升级泌尿系统，以满足这一可预见且不断扩大的切除和消融系统市场需求。根据联合国2024年7月发布的《2024年世界人口展望概要》，预计到2050年，65岁及以上人口的比例将达到约16%，这将显着扩大BPH的主要风险人口。

随着人口结构的变化，由于患者希望缩短復原时间，对微创、非手术治疗方法的治疗方法显着增加。这一趋势正推动市场从传统的经尿道切除术机器人辅助水刀消融术和前列腺尿道提升装置等先进技术，而专注于这些平台的公司数量也在迅速增长。例如，PROCEPT BioRobotics公司在2024年2月报告称，其2023财年机器人系统收入达到1.362亿美元，年增82%。波士顿科学公司也宣布，其2023年泌尿系统和骨盆底健康领域的净销售额为19.5亿美元，进一步印证了该技术的广泛应用。

市场挑战

良性前列腺增生（BPH）治疗设备全球市场成长的主要挑战在于先进手术技术所需的大量资金投入。最先进的雷射治疗主机和机器人系统采集费用及持续维护成本高昂，构成了医疗机构推广应用的重大经济障碍，迫使预算紧张的医疗机构仔细评估此类高成本设备的投资回报率。考虑到初始成本与医疗机构的财务现实，许多医疗机构被迫推迟采购，继续依赖经尿道切除术等更为传统（成本更低）的方法，从而阻碍了更高效解决方案的市场渗透。

由于偿还结构的收紧，可用于再投资的资金减少，使得证明这些高额资本投资合理性的难度进一步增加。据美国泌尿系统协会称，2024年联邦医疗保险（Medicare）医生报销係数将下降约3.37%，降至32.74美元，低于上年度。报销率的下降直接影响泌尿系统诊所和医院的收入，严重限制了它们承担先进良性前列腺增生治疗系统相关高昂成本的能力，并直接阻碍了市场扩张。

市场趋势

将人工智慧 (AI) 整合到机器人水刀消融系统中，标誌着一个变革性的转折点。透过将机器学习演算法整合到机器人主机中，可以实现优化的治疗计划和即时组织切除，从而达到超越人类能力的精准度。这项技术利用庞大的解剖影像资料集，帮助外科医生绘製前列腺轮廓，提高水刀消融术的安全性和一致性。例如，PROCEPT BioRobotics 公司于 2024 年 8 月宣布其人工智慧驱动的 HYDROS 机器人系统已获得 FDA核准。该系统利用超过 5 万个真实临床数据点的洞察，为良性前列腺增生 (BPH) 的治疗提供先进的影像引导和预测性工作流程。

同时，临时性镍钛合金植入装置的商业化正在改变微创治疗方式，它无需永久植入，也不会造成热损伤，即可缓解症状。这些装置能够暂时再形成前列腺尿道，并因其能够维持性功能和实现门诊快速康復而日益普及，促使市场参与者积极争取合约以确保市场准入。作为这一趋势的象征，奥林巴斯公司于2024年3月宣布，其镍钛合金临时性装置已在美国获得13份集团采购组织（GPO）合约。这显着扩大了这种非永久性治疗方法的商业性应用范围。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：良性前列腺增生（BPH）治疗器材全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（雷射设备、微波设备、高频设备、其他）
    • 依最终使用者（医院/诊所、门诊中心、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美良性前列腺增生（BPH）治疗设备市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章 欧洲良性摄护腺增生（BPH）治疗设备市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区良性摄护腺增生（BPH）治疗器材市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章 中东和非洲良性前列腺增生（BPH）治疗设备市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲良性摄护腺增生（BPH）治疗设备市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球良性前列腺增生（BPH）治疗设备市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Urologix, LLC
  • Olympus Corporation
  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Zenflow Inc.
  • Sonablate Corporation
  • Richard Wolf Gmbh
  • Karl Storz SE
  • Terumo Medical Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 20083

The Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market is projected to expand from USD 11.56 Billion in 2025 to USD 14.98 Billion by 2031, reflecting a compound annual growth rate of 4.41%. This market comprises medical devices employed for both the minimally invasive and surgical management of enlarged prostate glands, including technologies such as resectoscopes, laser systems, and radiofrequency ablation devices. The primary catalysts driving this growth are a rapidly aging global population and a rising preference for minimally invasive procedures that facilitate faster patient recovery, a demand heavily influenced by the high incidence of BPH among older men. For instance, the American Urological Association reported in 2024 that the prevalence of benign prostatic hyperplasia and related lower urinary tract symptoms in men aged 65 and older ranged between 29% and 35%.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 11.56 Billion
Market Size 2031USD 14.98 Billion
CAGR 2026-20314.41%
Fastest Growing SegmentLaser based equipment
Largest MarketNorth America

Despite these positive demand metrics, a major obstacle hindering broader market expansion is the significant capital expenditure necessary for advanced surgical technologies. The high costs associated with acquiring and maintaining modern laser consoles and robotic systems can restrict adoption rates, particularly within healthcare facilities operating with tight procurement budgets. Consequently, this financial barrier frequently compels providers in cost-sensitive areas to depend on traditional, less efficient methodologies, thereby decelerating the penetration of newer equipment solutions.

Market Driver

The rising prevalence of benign prostatic hyperplasia is fundamentally propelled by the rapid aging of the global male population, requiring a sustained increase in the deployment of diagnostic and therapeutic equipment. As life expectancy increases, the number of patients needing intervention for lower urinary tract symptoms grows, necessitating that healthcare providers upgrade their urology departments to address this predictable and expanding addressable market for resectoscopes and ablation systems. According to the United Nations' "World Population Prospects 2024: Summary of Results" published in July 2024, the proportion of the global population aged 65 years or older is expected to increase to nearly 16% by 2050, significantly widening the primary demographic susceptible to prostate enlargement.

Alongside demographic changes, there is a distinct surge in demand for minimally invasive and non-surgical treatment options, driven by patient preference for procedures that offer reduced recovery times. This trend is steering the market toward advanced technologies, such as robotic-assisted waterjet ablation and prostatic urethral lift devices, and away from traditional transurethral resection, leading to substantial adoption rates for companies specializing in these platforms. For example, PROCEPT BioRobotics reported in February 2024 that revenue for their robotic systems reached $136.2 million for the fiscal year 2023, an 82% increase over the prior year, while Boston Scientific reported net sales of $1.95 billion for their Urology and Pelvic Health segment in 2023, further validating this technological uptake.

Market Challenge

The primary challenge inhibiting the growth of the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market is the substantial capital expenditure required for advanced surgical technologies. The significant acquisition and ongoing maintenance costs linked to modern laser consoles and robotic systems establish a formidable financial barrier to adoption, requiring healthcare facilities with constrained budgets to critically assess the return on investment for such capital-intensive equipment. When the upfront costs are balanced against hospital financial realities, many providers are forced to defer purchases and continue relying on traditional, less expensive methodologies like transurethral resection, which stalls the market penetration of more efficient solutions.

This difficulty in justifying high-value acquisitions is further aggravated by tightening reimbursement structures that diminish available capital for reinvestment. According to the American Urological Association, the Medicare Physician Fee Schedule conversion factor was reduced by approximately 3.37% in 2024, dropping to $32.74 from the previous year. Such reductions in payment rates directly affect the revenue streams of urology practices and hospitals, significantly restricting their ability to absorb the high costs associated with advanced BPH treatment systems and directly impeding market expansion.

Market Trends

The integration of Artificial Intelligence into Robotic Aquablation Systems marks a transformative shift, elevating procedural precision beyond human limitations by embedding machine learning algorithms into robotic consoles to optimize treatment planning and real-time tissue resection. This technology leverages extensive datasets of anatomical imagery to assist surgeons in mapping prostate contours, thereby improving safety and consistency during waterjet ablation. For instance, PROCEPT BioRobotics announced in August 2024 the FDA clearance of the HYDROS Robotic System, an AI-powered platform that utilizes insights from over 50,000 real-world procedures to provide advanced image guidance and predictive workflows for treating benign prostatic hyperplasia.

Concurrently, the commercialization of Temporary Implantable Nitinol Devices is reshaping minimally invasive therapies by providing symptom relief without the need for permanent implants or causing thermal damage. These devices, which temporarily reshape the prostatic urethra, are becoming increasingly popular due to their ability to preserve sexual function and facilitate rapid recovery in outpatient settings, leading market players to aggressively secure contracts to ensure accessibility. Highlighting this trend, Olympus announced in March 2024 that its temporary nitinol device had secured placement on 13 Group Purchasing Organization contracts in the United States, significantly broadening the commercial reach of this non-permanent therapeutic option.

Key Market Players

  • Urologix, LLC
  • Olympus Corporation
  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Zenflow Inc.
  • Sonablate Corporation
  • Richard Wolf Gmbh
  • Karl Storz SE
  • Terumo Medical Corporation

Report Scope

In this report, the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By Type

  • Laser-based Equipment
  • Microwave-based Equipment
  • Radiofrequency-based Equipment
  • Other

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By End user

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market.

Available Customizations:

Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Laser-based Equipment, Microwave-based Equipment, Radiofrequency-based Equipment, Other)
    • 5.2.2. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End user
    • 6.3.2. Canada Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End user
    • 6.3.3. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End user

7. Europe Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End user
    • 7.3.2. France Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End user
    • 7.3.3. United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End user
    • 7.3.4. Italy Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End user
    • 7.3.5. Spain Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End user

8. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End user
    • 8.3.2. India Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End user
    • 8.3.3. Japan Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End user
    • 8.3.4. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End user
    • 8.3.5. Australia Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End user

9. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End user
    • 9.3.2. UAE Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End user
    • 9.3.3. South Africa Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End user

10. South America Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End user
    • 10.3.2. Colombia Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End user
    • 10.3.3. Argentina Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Urologix, LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Olympus Corporation
  • 15.3. Boston Scientific Corporation
  • 15.4. Teleflex Incorporated
  • 15.5. Zenflow Inc.
  • 15.6. Sonablate Corporation
  • 15.7. Richard Wolf Gmbh
  • 15.8. Karl Storz SE
  • 15.9. Terumo Medical Corporation

16. Strategic Recommendations

17. About Us & Disclaimer